Influence of angiotensin II on the gut microbiome: modest effects in comparison to experimental factors

• Published in: Cardiovascular research Vol. 120; no. 10; pp. 1155 - 1163
• Main Authors: R Muralitharan, Rikeish, Nakai, Michael E, Snelson, Matthew, Zheng, Tenghao, Dinakis, Evany, Xie, Liang, Jama, Hamdi, Paterson, Madeleine, Shihata, Waled, Wassef, Flavia, Vinh, Antony, Drummond, Grant R, Kaye, David M, Mackay, Charles R, Marques, Francine Z
• Format: Journal Article
• Language: English
• Published: UK Oxford University Press 02.09.2024
• Subjects: Angiotensin II - pharmacology; Animals; Bacteria - classification; Bacteria - drug effects; Bacteria - genetics; Bacteria - growth & development; Bacteria - metabolism; Disease Models, Animal; Dysbiosis; Female; Gastrointestinal Microbiome - drug effects; Hypertension - drug therapy; Hypertension - metabolism; Hypertension - microbiology; Hypertension - physiopathology; Intestines - drug effects; Intestines - microbiology; Male; Mice, Inbred C57BL; Original; Retrospective Studies; Ribotyping; RNA, Ribosomal, 16S - genetics; Hypertension; Animal models; Microbiota; Microbiome
• ISSN: 0008-6363; 1755-3245; 1755-3245
• DOI: 10.1093/cvr/cvae062

Abstract Aims Animal models are regularly used to test the role of the gut microbiome in hypertension. Small-scale pre-clinical studies have investigated changes to the gut microbiome in the angiotensin II hypertensive model. However, the gut microbiome is influenced by internal and external experimental factors, which are not regularly considered in the study design. Once these factors are accounted for, it is unclear if microbiome signatures are reproduceable. We aimed to determine the influence of angiotensin II treatment on the gut microbiome using a large and diverse cohort of mice and to quantify the magnitude by which other factors contribute to microbiome variations. Methods and results We conducted a retrospective study to establish a diverse mouse cohort resembling large human studies. We sequenced the V4 region of the 16S rRNA gene from 538 samples across the gastrointestinal tract of 303 male and female C57BL/6J mice randomized into sham or angiotensin II treatment from different genotypes, diets, animal facilities, and age groups. Analysing over 17 million sequencing reads, we observed that angiotensin II treatment influenced α-diversity (P = 0.0137) and β-diversity (i.e. composition of the microbiome, P < 0.001). Bacterial abundance analysis revealed patterns consistent with a reduction in short-chain fatty acid producers, microbial metabolites that lower blood pressure. Furthermore, animal facility, genotype, diet, age, sex, intestinal sampling site, and sequencing batch had significant effects on both α- and β-diversity (all P < 0.001). Sampling site (6.8%) and diet (6%) had the largest impact on the microbiome, while angiotensin II and sex had the smallest effect (each 0.4%). Conclusion Our large-scale data confirmed findings from small-scale studies that angiotensin II impacted the gut microbiome. However, this effect was modest relative to most of the other factors studied. Accounting for these factors in future pre-clinical hypertensive studies will increase the likelihood that microbiome findings are replicable and translatable. Graphical Abstract Graphical Abstract